| | |
Page
|
| |||
PROSPECTUS SUPPLEMENT
|
| | | | | | |
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-13 | | | |
| | | | S-17 | | | |
| | | | S-18 | | | |
| | | | S-20 | | | |
| | | | S-36 | | | |
| | | | S-41 | | | |
| | | | S-48 | | | |
| | | | S-48 | | | |
| | | | S-49 | | | |
| | | | S-50 | | | |
| | | | S-51 | | | |
| | | | S-51 | | |
| | |
Page
|
| |||
PROSPECTUS
|
| | | | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
Experts | | | | | 12 | | |
Condition
|
| |
Principal Markets
|
|
Rheumatoid arthritis (moderate to severe) | | | North America, European Union | |
Psoriatic arthritis | | | North America, European Union | |
Ankylosing spondylitis | | | North America, European Union | |
Adult Crohn’s disease (moderate to severe) | | | North America, European Union | |
Plaque psoriasis (moderate to severe chronic) | | | North America, European Union | |
Juvenile idiopathic arthritis (moderate to severe polyarticular)
|
| | North America, European Union | |
Ulcerative colitis (moderate to severe) | | | North America, European Union | |
Axial spondyloarthropathy | | | European Union | |
Pediatric Crohn’s disease (moderate to severe) | | | North America, European Union | |
Hidradenitis suppurativa (moderate to severe) | | | North America, European Union | |
Pediatric enthesitis-related arthritis | | | European Union | |
Condition
|
| |
Principal Markets
|
|
Non-infectious intermediate, posterior and panuveitis | | | North America, European Union | |
Pediatric ulcerative colitis (moderate to severe) | | | U.S., Canada, European Union | |
Pediatric uveitis | | | North America, European Union | |
Condition
|
| |
Principal Markets
|
|
Plaque psoriasis (moderate to severe) | | | North America, European Union, Japan | |
Psoriatic arthritis | | | U.S., European Union | |
Crohn’s disease (moderate to severe) | | | U.S., Canada, European Union | |
Condition
|
| |
Principal Markets
|
|
Rheumatoid arthritis (moderate to severe) | | | North America, European Union, Japan | |
Psoriatic arthritis | | | U.S., Canada, European Union, Japan | |
Ankylosing spondylitis | | | U.S., European Union | |
Atopic dermatitis (moderate to severe) | | | U.S., Canada, European Union, Japan | |
Axial spondyloarthropathy | | | U.S., European Union | |
Ulcerative colitis (moderate to severe) | | | U.S., European Union | |
Crohn’s disease (moderate to severe) | | | U.S., European Union | |
| | |
As of December 31, 2023
|
| |||||||||
(dollars in millions)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
Cash and equivalents
|
| | | $ | 12,814 | | | | | $ | | | |
Total debt and lease obligations: | | | | | | | | | | | | | |
Commercial paper(a)
|
| | | | — | | | | | | — | | |
Revolving credit facility (up to $5 billion)
|
| | | | — | | | | | | — | | |
Term loan facility
|
| | | | 2,000 | | | | | | 2,000 | | |
New term loan facility(a)
|
| | | | — | | | | | | — | | |
3.75% senior notes due 2023
|
| | | | — | | | | | | — | | |
1.50% senior euro notes due 2023 (€500 principal)
|
| | | | — | | | | | | — | | |
2.60% senior notes due 2024
|
| | | | 3,750 | | | | | | 3,750 | | |
1.375% senior euro notes due 2024 (€1,450 principal)(b)(c)
|
| | | | 1,610 | | | | | | 1,610 | | |
3.85% senior notes due 2024
|
| | | | 1,032 | | | | | | 1,032 | | |
1.25% senior euro notes due 2024 (€700 principal)(b)(c)
|
| | | | 777 | | | | | | 777 | | |
3.60% senior notes due 2025
|
| | | | 3,750 | | | | | | 3,750 | | |
3.80% senior notes due 2025
|
| | | | 3,021 | | | | | | 3,021 | | |
2.95% senior notes due 2026
|
| | | | 4,000 | | | | | | 4,000 | | |
3.20% senior notes due 2026
|
| | | | 2,000 | | | | | | 2,000 | | |
0.75% senior euro notes due 2027 (€750 principal)(b)
|
| | | | 833 | | | | | | 833 | | |
4.25% senior notes due 2028
|
| | | | 1,750 | | | | | | 1,750 | | |
2.125% senior euro notes due 2028 (€750 principal)(b)
|
| | | | 833 | | | | | | 833 | | |
2.625% senior euro notes due 2028 (€500 principal)(b)
|
| | | | 555 | | | | | | 555 | | |
3.20% senior notes due 2029
|
| | | | 5,500 | | | | | | 5,500 | | |
2.125% senior euro notes due 2029 (€550 principal)(b)
|
| | | | 611 | | | | | | 611 | | |
1.25% senior euro notes due 2031 (€650 principal)(b)
|
| | | | 722 | | | | | | 722 | | |
4.55% senior notes due 2035
|
| | | | 1,789 | | | | | | 1,789 | | |
4.50% senior notes due 2035
|
| | | | 2,500 | | | | | | 2,500 | | |
4.30% senior notes due 2036
|
| | | | 1,000 | | | | | | 1,000 | | |
4.05% senior notes due 2039
|
| | | | 4,000 | | | | | | 4,000 | | |
4.40% senior notes due 2042
|
| | | | 2,600 | | | | | | 2,600 | | |
4.625% senior notes due 2042
|
| | | | 457 | | | | | | 457 | | |
4.85% senior notes due 2044
|
| | | | 1,074 | | | | | | 1,074 | | |
| | |
As of December 31, 2023
|
| |||||||||
(dollars in millions)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
4.70% senior notes due 2045
|
| | | | 2,700 | | | | | | 2,700 | | |
4.75% senior notes due 2045
|
| | | | 881 | | | | | | 881 | | |
4.45% senior notes due 2046
|
| | | | 2,000 | | | | | | 2,000 | | |
4.875% senior notes due 2048
|
| | | | 1,750 | | | | | | 1,750 | | |
4.25% senior notes due 2049
|
| | | | 5,750 | | | | | | 5,750 | | |
Notes offered hereby:
|
| | | | | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
% senior notes due 20
|
| | | | — | | | | | | | | |
Fair value hedges(c)
|
| | | | (266) | | | | | | (266) | | |
Unamortized bond discounts(c)
|
| | | | (106) | | | | | | (106) | | |
Unamortized deferred financing costs(c)
|
| | | | (198) | | | | | | (198) | | |
Unamortized bond premiums(c)
|
| | | | 668 | | | | | | 668 | | |
Other(c)
|
| | | | 42 | | | | | | 42 | | |
Stockholders’ equity
|
| | | | 10,360 | | | | | | 10,360 | | |
Total capitalization
|
| | | $ | 69,745 | | | | | | | | |
|
Underwriter
|
| |
Principal
Amount of 20 Notes |
| |
Principal
Amount of 20 Notes |
| |
Principal
Amount of 20 Notes |
| |
Principal
Amount of 20 Notes |
| |
Principal
Amount of 20 Notes |
| |
Principal
Amount of 20 Notes |
| ||||||||||||||||||
Morgan Stanley & Co. LLC
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||||
J.P. Morgan Securities LLC
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
BofA Securities, Inc.
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Citigroup Global Markets Inc.
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 12 | | |
O';28XEN]V*[VOF_XK:6);2?9T<0KZB#6J7*+%
MJ:9LCS*#UIH[-A6^^TVX"VV,:RB([<'=.2W25&'+*C[U+4@(4LC[#6H^W*6U
M^:)V5YFN>IG1:Y#I% * 4 H"I[J/^G+./TDO^@BKOD?8CW%3S?NR[S3L"_\
MW6,?I:!^,MUT7>27 IG34J
M2M(4@A25#4*'$$&N,ZC^T H!0"@/A+FP[>PN5/D-18K?%;[ZTMMI'G4H@"O4
MF]1XVEK.([B=6FT.",NM0KF,HO2-0W LRDO-\PX>G)_W21KV\JE*^QJ1IY==
M9K6ZNTXK<[7#IQ?800WCWVS7>>YH?OSHAV**HJMUABJ5]ZLDC3G5KQ<=TX%:
MO/RA(.E6;+92%"T:^L@;\S*UZ=74 5SWJ<.I_LA>80PMQZT1VJ5(XN-VZOP
MRG <8R,+YU72UPY3A[_$=80I8/G"M0:H-T-RR4>ILN-4MZ"?6C9JTFTP^4XM
M8,UL4S&LG@MW&RST&AE@=58L H!0"@,;?
M3VUVSY%;HUUM;_\ O8DQI#[1.FFO*L$ C7@1Q%9PG*#QB\&8RBI+!K$CIF?0
M[M;?W')6,3)V+R5DD,M*$V&"?(T^?$''N#P%2U7-;8^;"1'6